Junshi Biopharma’s JS212 for injection clinical trial approved
March 24, 2025
Source: drugdu
47
On the evening of March 20, Junshi Biopharma (688180) announced that the company received the "Notice of Approval for Drug Clinical Trial" approved and issued by the National Medical Products Administration, and the clinical trial application for JS212 for injection was approved.
The announcement shows that JS212 is a recombinant humanized anti-epidermal growth factor receptor (hereinafter referred to as "EGFR") and human epidermal growth factor receptor 3 (hereinafter referred to as "HER3") bispecific antibody-drug conjugate (hereinafter referred to as "ADC"), which is mainly used for the treatment of advanced malignant solid tumors. Compared with single-target ADC drugs, JS212 can exert tumor suppression by binding to EGFR or HER3, and is expected to be effective for a wider range of tumors, and is expected to overcome drug resistance. Preclinical studies have shown that JS212 has high affinity and specific binding to EGFR and HER3, and has demonstrated significant tumor suppression in multiple animal models. At the same time, JS212 has good and acceptable safety.
https://finance.eastmoney.com/a/202503203351390171.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- 6 domestic ADCs successfully go global April 3, 2025
- Medical equipment giant begins layoffs and factory closures April 3, 2025
- Cultivate “Innovation Skills” and Cultivate “Conscience Seedlings” April 3, 2025
- Zhifei Biotech’s adjuvanted trivalent influenza vaccine has obtained clinical trial approval, which is expected to further enrich the company’s virus vaccine varieties April 3, 2025
- Under the vaccine price war, the performance of the leading influenza vaccine company Hualan Vaccine in 2024 has stalled April 3, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
